176 related articles for article (PubMed ID: 28796401)
1. Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma.
Kerr C; Adhikary G; Grun D; George N; Eckert RL
Mol Carcinog; 2018 Jan; 57(1):3-11. PubMed ID: 28796401
[TBL] [Abstract][Full Text] [Related]
2. Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Saha K; Fisher ML; Adhikary G; Grun D; Eckert RL
Carcinogenesis; 2017 Aug; 38(8):827-836. PubMed ID: 28854561
[TBL] [Abstract][Full Text] [Related]
3. ACTL6A suppresses p21
Shrestha S; Adhikary G; Xu W; Kandasamy S; Eckert RL
Oncogene; 2020 Sep; 39(36):5855-5866. PubMed ID: 32616890
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
Rorke EA; Adhikary G; Szmacinski H; Lakowicz JR; Weber DJ; Godoy-Ruiz R; Puranik P; Keillor JW; Gates EWJ; Eckert RL
Mol Carcinog; 2022 Jan; 61(1):19-32. PubMed ID: 34610184
[TBL] [Abstract][Full Text] [Related]
5. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
[TBL] [Abstract][Full Text] [Related]
6. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
Islam SS; Mokhtari RB; Akbari P; Hatina J; Yeger H; Farhat WA
Target Oncol; 2016 Apr; 11(2):209-27. PubMed ID: 26453055
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.
Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F
Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway.
Wang L; Tian Z; Yang Q; Li H; Guan H; Shi B; Hou P; Ji M
Oncotarget; 2015 Sep; 6(28):25917-31. PubMed ID: 26312762
[TBL] [Abstract][Full Text] [Related]
10. Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis.
Chen L; Chan LS; Lung HL; Yip TTC; Ngan RKC; Wong JWC; Lo KW; Ng WT; Lee AWM; Tsao GSW; Lung ML; Mak NK
Phytomedicine; 2019 Oct; 63():153058. PubMed ID: 31394414
[TBL] [Abstract][Full Text] [Related]
11. Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.
Bayat Mokhtari R; Baluch N; Morgatskaya E; Kumar S; Sparaneo A; Muscarella LA; Zhao S; Cheng HL; Das B; Yeger H
BMC Cancer; 2019 Aug; 19(1):864. PubMed ID: 31470802
[TBL] [Abstract][Full Text] [Related]
12. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo.
Vasvari GP; Dyckhoff G; Kashfi F; Lemke B; Lohr J; Helmke BM; Schirrmacher V; Plinkert PK; Beckhove P; Herold-Mende CC
Int J Cancer; 2007 Oct; 121(8):1697-704. PubMed ID: 17557286
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models.
Yee PS; Zainal NS; Gan CP; Lee BKB; Mun KS; Abraham MT; Ismail SM; Abdul Rahman ZA; Patel V; Cheong SC
Target Oncol; 2019 Apr; 14(2):223-235. PubMed ID: 30806895
[TBL] [Abstract][Full Text] [Related]
15. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
[TBL] [Abstract][Full Text] [Related]
16. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.
Račkauskas R; Zhou D; Ūselis S; Strupas K; Herr I; Schemmer P
Oncol Rep; 2017 Jun; 37(6):3660-3666. PubMed ID: 28498473
[TBL] [Abstract][Full Text] [Related]
19. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
20. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
Huang KJ; Kuo CH; Chen SH; Lin CY; Lee YR
J Cell Mol Med; 2018 Mar; 22(3):1894-1908. PubMed ID: 29363886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
